Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab. The main questions it aims to answer are:
Is low-dose blinatumomab more effective in patients with moderate-to-severe primary Sjögren's Syndrome who have an inadequate response or intolerance to conventional treatment? How does blinatumomab affect B cells, antibody levels, and the immune system in these participants?
Researchers will compare background treatment plus low-dose Blinatumomab with background treatment only to see if low-dose Blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome.
Participants will:
Receive background treatment for 24 weeks, including hydroxychloroquine 400 mg each day, methylprednisolone 8 mg each day, and sodium hyaluronate eye drops 4 times each day.
If assigned to the blinatumomab group, receive blinatumomab by continuous intravenous infusion for 5 days during week 1 and again for 5 days during week 3. The dose will be 9 micrograms per day.
Attend regular follow-up visits for clinical assessments, laboratory tests, and monitoring of treatment effectiveness and safety.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants who voluntarily agree to comply with the study protocol and provide written informed consent.
Male or female participants aged 18 to 70 years.
Diagnosis of primary Sjögren's syndrome according to the 2016 ACR/EULAR classification criteria.
Positive anti-SSA antibody at screening.
Moderate-to-severe active primary Sjögren's syndrome at screening, defined as an EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥5.
Inadequate response or intolerance to conventional treatment, defined as having received at least one immunomodulatory therapy, including glucocorticoids, cyclophosphamide, antimalarial drugs, azathioprine, or biologic agents, for more than 6 months before screening, with unsatisfactory disease control based on ESSDAI or other clinical assessments, or recurrence of active disease after an initial treatment response.
Diagnosis of dry eye disease according to the 2024 Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Dry Eye.
Moderate-to-severe dry eye disease at screening.
Laboratory values meeting all of the following requirements:
Both eyes will undergo study-related examinations and treatment.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
12 participants in 2 patient groups
Loading...
Central trial contact
Bowen Wang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal